MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 7:147-156, (2007)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.7.3.6
This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.
Right arrow Articles by St. Clair, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.
Right arrow Articles by St. Clair, D. K.
Reviews

Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues

Yumin Chen1, Paiboon Jungsuwadee1, Mary Vore1, D. Allan Butterfield2 and Daret K. St. Clair1

1 Graduate Center for Toxicology and
2 Deptartment of Chemistry, University of Kentucky, Lexington, KY 40506


Formula


   SUMMARY
TOP
 Summary
Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
 References
 
Injury to nontargeted tissues in chemotherapy often complicates cancer treatment by limiting therapeutic dosages of anticancer drugs and by impairing the quality of life of patients during and after treatment. Oxidative stress, directly or indirectly caused by chemotherapeutics as exemplified by doxorubicin, is one of the underlying mechanisms of the toxicity of anticancer drugs in noncancerous tissues, including the heart and brain. A comprehensive understanding of the mechanisms of oxidative injury to normal tissue will be essential for the improvement of strategies to prevent or attenuate the toxicity of chemotherapeutic agents without compromising their chemotherapeutic value.


   INTRODUCTION
TOP
 Summary
 Introduction
ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
 References
 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are generated in vivo from dioxygen (O2) and nitric oxide (NO), respectively. It is somewhat paradoxical that the reactive natures of both gases, which lies at the core of essential life processes, also engenders derivatives (i.e., certain ROS and RNS) that can be deleterious to life; such derivatives include superoxide radical (O2·–), hydrogen peroxide (H2O2), hydroxyl radical (HO·), alkoxyl/peroxyl radicals (RO·/ROO·), and peroxynitrite (ONOO–). The medical relevance of ROS and RNS is made further complex in that a great diversity of biophysical processes and conditions can support their production. For example, O2·– is primarily produced by incomplete reduction of O2 (1), whereas NO is generated from L-arginine via a nitric oxide synthase–catalyzed reaction (2). Many ROS/RNS are crucial signaling molecules, tightly regulated and essential to crosstalk mechanisms among multiple cellular pathways (3). In order to check the activities of ROS/RNS in vivo and maintain cellular redox conditions, antioxidant systems have evolved that consist of biological antioxidants (e.g., vitamin C, vitamin E, and glutathione) and antioxidant enzymes (e.g., super-oxide dismutase, catalase, and glutathione peroxidase). When the generation of ROS/RNS exceeds cellular adaptive and repair capacities—a condition that is referred to as oxidative stress—biological molecules such as nucleic acids, proteins, and membrane phospholipids become damaged through oxidative reactions. Oxidative stress results in the failure of normal cellular functions and even cell death.

The US Food and Drug Administration (FDA) has approved 132 anticancer drugs (a full list is available at http://www.fda.gov/cder/cancer/approved.htm). Fifty-six of these have been reported to induce oxidative stress, including the anthracyclines, cyclophosphamide, cisplatin, busulfan, mitomycin, fluorouracil, cytarabine, and bleomycin (Figure 1Go). Some chemotherapeutic agents, such as bleomycin (4), induce oxidative stress as a mechanism for killing cancer cells. However, certain chemotherapeutic agents, such as the anthracyclines (5–7), induce oxidative stress in nontargeted tissues and thereby lead to "normal tissue injury." Although chemotherapy improves the survival rates of cancer patients, oxidative stress–mediated impairment of normal tissues is a significant side effect and decreases the quality of life of patients. A better understanding of the mechanisms involved in oxidative injury to normal tissues is essential to the design of intervention strategies that will attenuate the toxicity of chemotherapeutic agents without compromising their anticancer efficacy.


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		Figure 1. Anticancer drugs that cause oxidative stress. Cyclophosphamide and cisplatin are converted to reactive metabolites that cause DNA cross-linking and react with the thiol groups in enzymes and glutathione. Busulfan decreases glutathione levels. Mitomycin induces ROS generation through redox cycling of the quinone moiety. Cytarabine incorporates into DNA and acts as a chain terminator; following cytarabine-induced damage to DNA, ROS are generated in vivo. Bleomycin forms complexes with Fe2+ and O2 that break DNA strands and generate superoxide and hydroxyl radicals. In all, 56 of 132 FDA-approved anticancer drugs have been implicated in oxidative stress (as determined through Scinfinder Scholar using each drug name and the term "oxidative stress" as keywords). See text for details.

 
To address the problem of oxidative damage in normal tissues exposed to chemotherapeutics, we have studied doxorubicin (DOX, also called adriamycin), a representative of the anthracyclines, which remain one of the most effective anticancer drug families in clinical use. Other anthracyclines used in clinical practice include daunorubicin, epirubicin, idarubicin, aclarubicin, pirarubicin, and mitoxantrone (Figure 2Go). DOX kills cancer cells through DNA intercalation and inhibition of topoisomerase II (8), but its side effects include oxidative stress–mediated injuries to heart (5), kidney (6), and brain (7). DOX nevertheless remains an important component in most chemotherapeutic regimens, owing to its efficacy in treating a broad spectrum of cancers.


Figure 2
View larger version (14K):
[in this window]
[in a new window]

  		Figure 2. Anthracyclines in current clinical use. Doxorubicin and daunorubicin are two prime anthracyclines used as anticancer drugs. Doxorubicin is used in treatment of breast cancer, aggressive lymphomas, childhood solid tumors, and soft tissue sarcomas, whereas daunorubicin is used to treat acute lymphoblastic or myeloblastic leukemias. Structural analogs of doxorubicin and daunorubicin (i.e., epirubicin, pirarubicin, idarubicin, aclarubicin, and mitoxantrone) were developed in the search for chemotherapeutics with limited cardiotoxicity; the success of this search has been rather modest. See text for details.

 
Although many tissues are susceptible to the unintended effects of chemotherapy, here we will focus on heart and brain. Because cardiomyocytes and neurons are post-mitotic cells, major insults that befall them are generally irreversible and thus can irrevocably affect the functions of the heart and brain. Cardiotoxicity is well recognized in chemotherapy (9), especially in patients treated with anthracyclines, which can cause the dose-dependent development of dilated cardiomyopathy and congestive heart failure (10). Recent studies have revealed that brain tissue is similarly susceptible to chemotherapeutic agents, despite suppositions of protection via the blood–brain barrier (BBB) (11). Persistent changes in cognitive function, including memory loss, distractibility, and difficulty in performing multiple tasks, have been observed in breast cancer survivors after treatment with chemotherapeutic agents, including DOX (11–13). The term "chemobrain" has been used to describe the cognitive decline associated with chemotherapy (14, 15). Moreover, magnetic resonance imaging has revealed that chemotherapy has an influence on the structures of the brain (16–18), which might be related to cognitive impairments. In addition, positron emission tomography has shown defects in brain function in breast cancer patients five to ten years after chemotherapy (19, 20). Although the molecular basis for "chemobrain" remains elusive, oxidative stress has been thought to play a mechanistic role (7, 11, 21–23).


   ROS/RNS GENERATION AND DISTURBANCE OF REDOX STATUS IN CHEMOTHERAPY
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
 References
 
Oxidative stress results from an imbalance between the generation of ROS/RNS and their removal by the cellular antioxidant system. The heart and brain manifest distinct mechanisms of DOX-induced ROS/RNS production. In heart, DOX-induced production of ROS/RNS involves the interplay of multiple processes, including redox cycling of the quinone moiety of DOX, disturbance of iron metabolism, and DOX metabolites. In contrast, tumor necrosis factor-{alpha} (TNF-{alpha}) has been implicated in the generation of ROS/RNS in the brain (21).

MECHANISMS OF TOXICITY IN THE HEART
The heart is rich in mitochondria, which occupy about forty percent of the total intracellular volume of cardiomyocytes (24). DOX has a high affinity for cardiolipin, a negatively charged phospholipid abundant in the mitochondrial inner membrane (25), leading to mitochondrial accumulation of DOX (26). Under clinically relevant plasma DOX concentrations of 0.5–1 µM, intramitochondrial concentrations can reach approximately 50–100 µM. At these relatively high concentrations of DOX, the heart becomes a site of redox reactivity. Specifically, the quinone functionality of DOX is transformed, in the presence of NADH, into a semiquinone via one-electron reduction by complex I of the electron transport chain (27). The semiquinone form reacts with molecular oxygen to produce a superoxide radical (O2·–), whereby DOX returns to the quinone form. The cycling of DOX between qui-none and semiquinone forms generates large amounts of O2·– (Figure 3Go), which further give rise to a variety of active ROS/RNS species, including H2O2, ·OH, and ONOO– (28, 29). In heart tissue, several endogenous reductases (30) and the endothelial isoform of nitric oxide synthase (31) can catalyze the redox cycling of DOX.


Figure 3
View larger version (19K):
[in this window]
[in a new window]

  		Figure 3. DOX-induced generation of ROS/RNS in heart. Cleavage of the sugar residue and reduction of the carbonyl group at C13 produce DOX aglycone and doxorubicinol (DOXol), respectively. Redox cycling of DOX and its metabolites generates ROS including O2·– and H2O2. ROS and DOXol can affect iron metabolism and lead to increased levels of cellular free iron ions, which induce further ROS/RNS generation.

 
DOX also interferes with normal metabolic reactions that involve iron, a redox-active transition metal, again leading to ROS generation (Figure 3Go). DOX semiquinone, O2·–, and their byproduct H2O2 can trigger the release of iron from ferritin, an important iron storage protein (10), as well as from cytoplasmic aconitase, which contains a [4Fe-4S] cluster. Loss of the [4Fe-4S] cluster converts cytoplasmic aconitase into iron regulatory protein (IRP)-1. IRP1 binds with high affinity to conserved iron-responsive elements (IRE) in the untranslated regions of transferrin receptor (TfR) and ferritin mRNAs, stabilizing TfR mRNA but destabilizing ferritin mRNA (32, 33). As a consequence, iron uptake exceeds iron sequestration, so that increased cellular levels of free iron lead to production of ·OH via Fenton chemistry, contributing to oxidative stress and cytotoxicity.

Metabolic turnover of DOX per se is another factor leading to ROS generation. Aldoketo reductases convert the carbonyl group at C13 to a hydroxyl group, thereby conferring a secondary alcohol function upon DOX (Figure 3Go) (10). The secondary alcohol derivative of DOX is effective in releasing iron from the [4Fe-4S] cluster of cytoplasmic aconitase (34, 35), resulting in further disturbance of iron metabolism and further oxidative stress (36). DOX can also be metabolized into its aglycone form, which results from cleavage of the sugar residue off the parent compound (37). The lipophilic aglycone metabolite of DOX has a higher membrane diffusion capacity than its parent compound and can accumulate in the mitochondrial inner membrane. Diversion of electrons from the respiration chain leads to ROS formation and deterioration of the functional integrity of the respiration chain.

MECHANISMS OF TOXICITY IN THE BRAIN
In comparison with the multiple mechanisms proposed for DOX-induced ROS/RNS generation in the heart, much less is known about such mechanisms in the brain (11, 21, 22). It is generally believed that ATP-dependent transporters at the BBB prevent passage of DOX through the barrier (38), and indeed DOX has not been detected in the areas protected by the BBB, such as the cortex and the hippocampus (21, 39). In contrast, we have found increased levels of TNF-{alpha} in the cortex and the hippocampus of mice treated with DOX (21). Moreover, markers of oxidative stress, including protein carbonyl levels, protein-conjugated 4-hydroxy-2-nonenal (4-HNE; a product of lipid peroxidation), and protein nitrotyrosine are elevated in the brains of DOX-treated mice (22). It is therefore likely that oxidative stress in the brains of these animals results from indirect effects of DOX and that TNF-{alpha} is a mediator of DOX-induced ROS/RNS. Administration of DOX has also been shown to increase circulating levels of TNF-{alpha} (7, 21, 40). Circulating TNF-{alpha} can pass the BBB (41) and activate glial cells to initiate local production of TNF-{alpha} (42), which in turn induces nitric oxide synthase, leading to the generation of RNS (Figure 4Go) (7). Furthermore, the role of nitric oxide synthase in RNS production in the brain during DOX treatment is strongly supported by two independent investigations in rat models. In one study, daunorubicin, an analog of DOX (Figure 2Go), raises the level of nitric oxide synthase in the brain (43), whereas inhibition of nitric oxide synthase by aminoguanidine ameliorates DOX-induced oxidative stress in the brain (44). The role of circulating TNF-{alpha} in mediating ROS/RNS is supported by the fact that co-administration of anti-TNF-{alpha} antibody with DOX completely prevents TNF-{alpha} elevation and DOX-induced brain injury (21).


Figure 4
View larger version (75K):
[in this window]
[in a new window]

  		Figure 4. Proposed mechanism of DOX-induced oxidative stress in brain. DOX leads to increased levels of circulating TNF-{alpha}, which can pass the blood-brain barrier and trigger local production of TNF-{alpha} in the brain. Increased levels of TNF-{alpha} may in turn induce the expression of nitric oxide synthases, leading to oxidative stress.

 

   CELLULAR MODULATION OF OXIDATIVE STRESS
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
 References
 
Cellular antioxidants and antioxidant enzymes play a vital role in scavenging ROS/RNS and maintaining a balanced cellular redox status. ROS/RNS that arise during chemotherapy consume cellular antioxidants and lead to oxidative modification and inactivation of antioxidant enzymes. This cascade of events pushes the cellular redox status towards the direction of oxidative stress.

Glutathione, a ubiquitous thiol-containing tripeptide, functions directly as an antioxidant in vivo. Glutathione-dependent enzymes, such as glutathione peroxidase, glutathione reductase, and glutathione-S-transferase, utilize glutathione to neutralize ROS (45). Glutathione acts as a reductant to convert hydrogen peroxide into water and to reduce lipid peroxides to their corresponding alcohols; in these reactions, two molecules of glutathione must combine to form a disulfide bond (i.e., GSSG), which is catalyzed by glutathione peroxidase. To complete this redox cycle, glutathione reductase uses NADPH to catalyze the conversion of GSSG back into two molecules of glutathione. In addition, glutathione, by virtue of its nucleophilic thiol group, can conjugate directly with lipid oxidation products or xenobiotics to produce thioethers; these adduct reactions are catalyzed by glutathione-S-transferase and provide important mechanisms for the detoxification and excretion of toxic substances. The ROS that are produced in response to chemotherapeutic agents such as DOX decrease cellular glutathione reserves (44) and thereby escalate oxidative stress (46, 47). DOX administration further leads to a dose-dependent decrease of glutathione peroxidase activity in the heart (48) and glutathione-S-transferase activity in the brain (23); decreases in these enzyme activities presumably reflect mechanisms of oxidative stress. In brain tissue of DOX-treated mice, manganese superoxide dismutase (MnSOD), an essential mitochondrial antioxidant enzyme, has been found to be inhibited upon nitration (7). Tyr34 is vital for MnSOD activity, and its nitration impedes substrate binding (49).

ATP-dependent transporter proteins such as multidrug resistance–associated proteins (MRPs) also play important roles in maintaining the cellular redox balance by transporting glutathione-conjugated lipid oxidation products out of cells (50). We found, in the heart tissue of DOX-treated mice, that 4-HNE modifies and inhibits Mrp-1, thereby exacerbating DOX-induced oxidative stress (51). Moreover, levels of Mrp-1 are elevated in the brains of DOX-treated mice (22). Given that MRPs, together with P-glycoprotein (i.e., MDR1), are intrinsically expressed at the BBB to regulate drug distribution and efflux (52), these findings prompt the intriguing question as to whether chemotherapy-based inactivation of ATP-dependent transporter proteins compromises the integrity of the BBB, leading to drug accumulation in the brain and thus contributing to further oxidative stress.


   ROUTES TO OXIDATIVE DAMAGE OF NONTARGETED TISSUES
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
Protection against Chemotherapy...
 Summary
 References
 
DOX affects proteins at both the transcriptional and post-translational levels. Microarray analysis has shown that DOX can modulate the expression of cardiac proteins related to energy production and metabolism, calcium regulation, cell growth and death, cytoskeletal function, cell adhesion, and signal transduction (53). Among the affected proteins, enzymes involved in bioenergetic and metabolic pathways are of particular importance, because the maintenance and functionality of the heart require great inputs of energy (53–55). Disruption of metabolic pathways that normally support energy production, energy transfer, and energy utilization directly contribute to heart injury. At the transcriptional level, DOX decreases the expression of phospholipase C{delta} , a crucial enzyme for phosphoinositol signaling and calcium homeostasis (53). At the post-translational level, DOX-induced ROS can oxidize a susceptible cysteine residue (i.e., Cys278) of mitochondrial creatine kinase, thereby inactivating this pivotal, energy-regulating enzyme (54). Oxidative modification has also been implicated in the inhibition of NADH dehydrogenase in the heart (27). Through an emerging redox proteomic approach that combines the power of two-dimensional electrophoresis and immunochemistry, proteins with elevated oxidative modification markers, such as carbonyl levels, 4-HNE, and nitrotyrosine, have been identified (56). In a mouse model, redox proteomics showed that cardiac triose phosphate isomerase, ß-enolase, and electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO) become carbonylated after acute DOX treatment (55). Triose phosphate isomerase and ß-enolase operate within the glycolytic pathway: the isomerase catalyzes the interconversion between glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, and ß-enolase catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. ETF-QO is an iron–sulfur ([4Fe-4S]) flavoprotein, located at the inner mitochondrial membrane, that catalyzes electron transfer from ETF to co-enzyme Q, a process crucial to the metabolic oxidation of certain fatty acids and amino acids. Consequently, the proteomic identification of cardiac proteins that are inactivated following DOX treatment (55) suggests that ATP production would be compromised in heart, a suggestion that is indeed consistent with observed effects of DOX.

At the subcellular level, mitochondria are the main targets of DOX-induced oxidative stress. Electron micrographs clearly demonstrate that DOX causes profound damage to the organelle, including mitochondrial vacuolization, mitochondrial degeneration, and disruption of the mitochondrial membrane. Mitochondrial DNA (mtDNA) is also an important target for oxidative stress. The circular molecule of mtDNA within the human organelle consists of 16,569 base pairs (57) and encodes two rRNAs, twenty-two tRNAs, and thirteen polypeptides, all of which are essential to oxidative phosphorylation (58). Compared with nuclear DNA (nDNA), mtDNA is more susceptible to oxidative damage, owing to its proximity to the site of ROS generation, its lack of introns and histones, and the limited DNA repair capacities in mitochondria (59). Consequently, the mutation rate of mammalian mtDNA is ten- to seventeenfold higher than that of nDNA (60). In the heart, DOX-induced oxidative stress causes formation of 8-hydroxydeoxyguanosine (61) and mtDNA deletions (62, 63); significantly, levels of 8-hydroxydeoxyguanosine persist after termination of DOX treatment (64). The heightened, oxidation-sensitive mutability of mtDNA has obvious implications for cellular energy production. Upon accumulation of insults to mtDNA, cellular capacities for energy production cannot meet the constant physical demands placed on the heart, and cardiac hypertrophy and heart failure ensue (65). In the brain, there is no direct evidence of mtDNA damage in DOX treatment, but research into this question has only just begun (7, 21). Intriguingly, age-related neurodegenerative diseases such as Parkinson disease and amyotrophic lateral sclerosis are characterized by mtDNA oxidative damage and neuronal dysfunction (66). It is tempting to speculate that mtDNA oxidative damage might play a vital role in the cytotoxicity of DOX in the brain.


   PROTECTION AGAINST CHEMOTHERAPY-INDUCED OXIDATIVE DAMAGE
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
Summary
 References
 
Total cumulative dose, rate of administration, duration of chemotherapy, and concomitant use of other cardiotoxic drugs are well-recognized risk factors for DOX cardiotoxicity (67). Several strategies have been applied to mitigate the side effects of DOX. The maximum cumulative dose of DOX is 450–550 mg/m2 (68); there is some evidence that slow (i.e., over 48 or 96 hours) continuous infusion of DOX may be less cardiotoxic in adults (69) [although not in children (70)]. Otherwise, intensive research has shown only moderate success in finding analogs of DOX that have equivalent anticancer activity but less toxicity. Among DOX analogs, epirubicin has a higher cumulative dose than DOX, but its activity against breast cancer is lower (71, 72); idarubicin is a more potent anticancer drug, but its cardiotoxicity is no less than DOX (73, 74); mitoxantrone also has cardiotoxicity similar to DOX. These analogs still manifest toxicity in brain tissue (75). (See Figure 2Go for structures.)

Insights into the key steps mediating DOX-induced oxidative stress have suggested mechanism-based strategies to prevent normal tissue damage (Figure 5Go). One strategy is to disrupt the ROS propagation chain. Dexrazoxane (DRZ), an iron chelator, has been cooperatively used with DOX to chelate the free iron ions released by DOX and its metabolites, and thus to inhibit Fe2+-related ROS generation without interfering with the anticancer potency of DOX (76). DRZ has demonstrated efficacy in ameliorating both acute and chronic DOX cardiotoxicity in mammalian models including mouse, dog, swine (77), and in human cancer patients (76). A recent report shows, however, that DRZ may be risky to use with certain cancers (78), demonstrating the necessity for novel intervention methods. The discovery that TNF-{alpha} mediates the toxicity of DOX in the brain suggests that an anti-TNF-{alpha} antibody could be a potential modality to quench oxidative stress in the brain, as recently demonstrated by the preliminary success of the proof-of-concept study in a mouse model (21). In addition, the insight that isoforms of nitric oxide synthase may be involved in RNS production and oxidative stress in the brain (7, 79, 80) suggests that selective inhibition of these enzyme activities could be therapeutic (44).


Figure 5
View larger version (11K):
[in this window]
[in a new window]

  		Figure 5. Mechanism-based interventions into DOX-induced oxidative damage. Iron chelators reduce free cellular iron ions and disrupt the propagation of ROS/RNS and are thus used to reduce DOX cardiotoxicity. The efficacies of antioxidants to decrease oxidative damage in the heart and brain are now also under intensive study. Modulation of circulating TNF-{alpha} may be an intervention modality to reduce DOX-induced oxidative damage in the brain. See text for details.

 
The efficacy of antioxidant enzymes to reduce DOX-induced cardiac injuries has been demonstrated in transgenic mice that overexpress MnSOD, catalase, metallothionein, or thioredoxin-1 (81–84). These valuable transgenic animal models clearly warrant further characterization and may reveal possible mechanisms by which these antioxidant enzymes protect the brain from DOX toxicity. Intervention strategies may include direct use of antioxidant enzyme mimetics. A cell-permeable SOD mimetic (i.e., MnTBAP) and a glutathione peroxidase mimetic (i.e., Ebselen) have been shown to protect cardiomyocytes from DOX-induced toxicity (85).

Co-administration of antioxidants or antioxidant precursors is another way to diminish oxidative stress by direct removal of DOX-induced ROS. Recently, grape seed proanthocyaniclins, a dietary antioxidant supplement, have been shown to enhance the anti-tumor activity of DOX and ameliorate DOX-induced myocardial oxidative stress in tumor-bearing mice (86). Pretreatment of mice with gamma-glutamyl-cysteine ethyl ester, a precursor of glutathione, increases brain glutathione levels and significantly decreases glutathione-S-transferase–facilitated protein oxidation and lipid peroxidation (23). These results demonstrate the feasibility of co-administration of antioxidants as a strategy to prevent nontargeted tissues from DOX-induced oxidative stress.


   SUMMARY
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
References
 
Oxidative stress is one mechanism by which many chemotherapeutic agents kill cancer cells. As a side effect, however, these chemotherapeutic agents can also place nontargeted (i.e., noncancerous) tissues under conditions of oxidative stress and thereby undermine the health of organs such as the heart and brain. Such damage not only limits the effective dosage of chemotherapeutics, but also compromises the quality of life of cancer patients after chemotherapy. Chemotherapy-induced ROS/RNS species [and their concomitant oxidative damage to proteins (including anti-oxidant and energy-generating enzymes), lipids, nucleic acids, and larger cellular components (e.g., membranes and mitochondria)] are prime suspects in the toxic side effects of acute or chronic chemotherapeutic treatment. Intensive investigations to pursue the relationship between oxidative stress–generating anticancer drugs and damage to nontargeted tissues are greatly benefiting from modern technologies, including proteomic techniques. Novel intervention strategies to mitigate the potential side effect of chemotherapeutics on normal tissues are increasingly relying on our mechanistic insights into the roles of chemotherapeutics in promoting cellular oxidative stress.


Figure 6
Yumin Chen, PhD, is a postdoctoral scholar in the Department of Toxicology at the University of Kentucky. He performed his doctoral work in Biochemistry at Miami University. His research interests pertain to the biochemistry and toxicity of ROS/RNS. Paiboon Jungsuwadee, PhD, is a senior scientist in the Department. He received his degree in Pharmacology and Toxicology from the University of Vienna, Austria. His research interests span pharmacology and immunology. Daret St. Clair, PhD, is the James Graham Brown Foundation Endowed Chair in Neuroscience and Professor of Toxicology at the University of Kentucky. She has been active in the field of free radicals in biology and medicine for over fifteen years. Her research interests pertain to antioxidant enzymes, especially superoxide dismutase and its role in cancer. Mary Vore, PhD, is Professor and Chair of the Department of Toxicology at the University of Kentucky. Her studies address mechanisms of drug metabolism and detoxification, with a focus on hepatic transporters, their role in the elimination of xenobiotics, and the metabolism of endogenous substrates such as steroid conjugates and bile acids. Allan Butterfield, PhD, is the Alumni Professor of Biological Chemistry in the Department of Chemistry at the University of Kentucky. His expertise is in the field of oxidative stress and brain injury. His research has been focused on protein oxidation and its role in the development of diseases associated with neurodegeneration. Address correspondence to DSC. E-mail dstcl00{at}uky.edu; fax 859-323-1059.


   ACKNOWLEDGMENTS
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
 References
 
This work is supported by NIH grants CA 49797 and CA 94853.


   References
TOP
 Summary
 Introduction
 ROS/RNS Generation and...
 Cellular Modulation of Oxidative...
 Routes to Oxidative Damage...
 Protection against Chemotherapy...
 Summary
 References
 

  1. Raha, S., Robinson, B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends. Biochem. Sci. 25, 502–508 (2000).[CrossRef][Medline]
  2. Pryor, W.A., Houk, K.N., Foote, C.S. et al. Free radical biology and medicine: It’s a gas, man! Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R491–R511 (2006).[Abstract/Free Full Text]
  3. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T.D., Mazur, M., Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44–84 (2007).[CrossRef][Medline]
  4. Hug, H., Strand, S., Grambihler, A. et al. Reactive oxygen intermediates are involved in the induction of cd95 ligand mrna expression by cytostatic drugs in hepatoma cells. J. Biol. Chem. 272, 28191–28193 (1997).[Abstract/Free Full Text]
  5. Singal, P. K., Iliskovic, N., Li, T. M., Kumar, D. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEB J. 11, 931–936 (1997).[Abstract]
  6. Shri, N.G., Mohammed Ali, A.-B., Xiaogu, D., Edward, S., Mohr, F.C., and Solomon, B.M. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother. Pharmacol. V53, 141–150 (2004).[CrossRef][Medline]
  7. Tangpong, J., Cole, M.P., Sultana, R. et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain. J. Neurochem. 100, 191–201 (2007).[CrossRef][Medline]
  8. Darpa, P.and Liu, L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 989, 163–177 (1989).[Medline]
  9. Simbre, I.I.V.C., Duffy, S.A., Dadlani, G.H., Miller, T.L., and Lipshultz, S.E. Cardiotoxicity of cancer chemotherapy: Implications for children. Pediatr. Drugs 7, 187 (2005).[CrossRef]
  10. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229 (2004). This is a comprehensive review paper, offering detailed discussion on the development of anthracyclines as anticancer drugs and the progress in understanding their cardiotoxicity.[Abstract/Free Full Text]
  11. Ahles, T.A. and Saykin, A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 7, 192 (2007).[CrossRef][Medline]
  12. Ahles, T.A., Saykin, A.J., Furstenberg, C.T. et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 20, 485–493 (2002).[Abstract/Free Full Text]
  13. Tannock, I.F., Ahles, T.A., Ganz, P.A., and van Dam, F.S. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. Clin. Oncol. 22, 2233–2239 (2004).[CrossRef]
  14. Schagen, S. B., van Dam, F., Muller, M. J., Boogerd, W., Lindeboom, J., and Bruning, P. F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85, 640–650 (1999).[CrossRef][Medline]
  15. Wefel, J.S., Lenzi, R,. Theriault, R., Buzdar, A.U., Cruickshank, S., and Meyers, C.A. "Chemobrain" in breast carcinoma?: A prologue. Cancer 101, 466–475 (2004).[CrossRef][Medline]
  16. Inagaki, M., Yoshikawa, E., Matsuoka, Y. et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109, 146–156 (2007).[CrossRef][Medline]
  17. Brown, M.S., Stemmer, S.M., Simon, J.H. et al. White matter disease induced by high-dose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. AJNR Am. J. Neuroradiol. 19, 217–221 (1998).[Abstract]
  18. Stemmer, S.M., Stears, J.C., Burton, B.S., Jones, R.B., and Simon, J.H. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am. J. Neuroradiol. 15, 1267–1273 (1994).[Abstract]
  19. Silverman, D.H., Dy, C.J., Castellon, S.A. et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10years after chemotherapy. Breast Cancer Res. Treat. 103, 303–311 (2007). This study revealed that alterations of brain metabolism in breast cancer survivors persist long after the completion of chemotherapy.[CrossRef][Medline]
  20. Castellon, S.A., Silverman, D.H., and Ganz, P.A. Breast cancer treatment and cognitive functioning: Current status and future challenges in assessment. Breast Cancer Res. Treat. 92, 199–206 (2005).[CrossRef][Medline]
  21. Tangpong, J., Cole, M.P., Sultana, R. et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobio. Dis. 23, 127–139 (2006). This paper provided direct biochemical evidence of DOX toxicity to the brain, revealed that circulating TNF-{alpha} mediates DOX-induced CNS injury, and implied that anti-TNF-{alpha} antibody might be used as a potential therapeutic intervention against circulating TNF-{alpha} –induced CNS effects.[CrossRef]
  22. Joshi, G., Sultana, R., Tangpong, J. et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: Insight into chemobrain. Free Rad. Res. 39, 1147–1154 (2005).[CrossRef][Medline]
  23. Joshi, G., Hardas, S., Sultana, R., St Clair, D. K.,Vore, M., Butterfield, D. A. Glutathione elevation by {gamma}-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. Neurosci. Res. 85, 497–503 (2007).[CrossRef]
  24. Goffart, S., von Kleist-Retzow, J.C., Wiesner, R.J. Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc. Res. 64, 198–207 (2004).[Abstract/Free Full Text]
  25. Parker, M.A., King, V., and Howard, K.P. Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers. Biochim. Biophys. Acta 1514, 206–216 (2001).[Medline]
  26. Sarvazyan, N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 271, H2079–2085 (1996).[Abstract/Free Full Text]
  27. Marcillat, O., Zhang, Y., and Davies, K.J. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem. J. 259, 181–189 (1989).[Medline]
  28. Vasquezvivar, J., Kalyanaraman, B., and Kennedy, M.C. Mitochondrial aconitase is a source of hydroxyl radical—an electron spin resonance investigation. J. Biol. Chem. 275, 14064–14069 (2000).[Abstract/Free Full Text]
  29. Doroshow, J.H. Anthracycline antibiotic-stimulated superoxide, hydrogen-peroxide, and hydroxyl radical production by nadh dehydrogenase. Cancer Res. 43, 4543–4551 (1983).[Abstract/Free Full Text]
  30. Doroshow, J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460–472 (1983).[Abstract/Free Full Text]
  31. Vasquezvivar, J., Martasek, P., Hogg, N., Masters, B.S., Pritchard, K.A., and Kalyanaraman, B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36, 11293–11297 (1997).[CrossRef][Medline]
  32. Corna, G., Galy, B., Hentze, M.W., Cairo, G. Irp1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice. J. Mol. Med. 84, 551–560 (2006).[CrossRef][Medline]
  33. Minotti, G., Recalcati, S., Mordente, A. et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J. 12, 541–552 (1998).[Abstract/Free Full Text]
  34. Minotti, G., Ronchi, R., Salvatorelli, E., Menna, P., and Cairo, G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 61, 8422–8428 (2001).[Abstract/Free Full Text]
  35. Minotti, G., Recalcati, S., Mordente, A. et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J. 12, 541–552 (1998).[Abstract/Free Full Text]
  36. Kotamraju, S., Chitambar, C.R., Kalivendi, S.V., Joseph, J., and Kalyanaraman, B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: Role of oxidant-induced iron signaling in apoptosis. J. Biol. Chem. 277, 17179–17187 (2002). This paper, together with references 34 and 35, demonstrated the mechanism whereby DOX and its metabolites disturb iron metabolism and lead to cardiotoxicity.[Abstract/Free Full Text]
  37. Lea, J.S., Rushton, F.A.P., Land, E.J., and Swallow, A.J. The reductive deglycosylation of adriamycin in aqueous-medium - a pulse-radiolysis study. Free Radic. Res. Commun. 8, 241–249 (1990).[Medline]
  38. Ohnishi, T., Tamai, I., Sakanaka, K. et al. In vivo and in vitro evidence for atp-dependency of p-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem. Pharmacol. 49, 1541–1544 (1995).[CrossRef][Medline]
  39. Bigotte, L., Olsson, Y. Cytofluorescence localization of adriamycin in the nervous system. Acta Neuropatho. V58, 193–202 (1982).[CrossRef]
  40. Usta, Y., Ismailoglu, U.B., Bakkaloglu, A. et al. Effects of pentoxifylline in adriamycin-induced renal disease in rats. Pediatr. Nephrol. 19, 840–843 (2004).[Medline]
  41. Osburg, B., Peiser, C., Domling, D. et al. Effect of endotoxin on expression of tnf receptors and transport of tnf-alpha at the blood-brain barrier of the rat. Am. J. Physiol. Endocrinol. Metab. 283, E899–908 (2002).[Abstract/Free Full Text]
  42. Szelenyi, J. Cytokines and the central nervous system. Brain Res. Bull. 54, 329–338 (2001).[CrossRef][Medline]
  43. Joshi, P., Vig, P.J.S., Veerisetty, V., Cameron, J.A., Sekhon, B.S., and Desaiah, D. Increase in brain nitric oxide synthase activity in daunorubicin-treated rats. Pharmacol. Toxicol. 78, 99–103 (1996). References 43 and 44 established the role of ROS/RNS in anthracycline toxicity in the CNS.[Medline]
  44. Abd El-Gawad, H. and El-Sawalhi, M.M. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: Role of amino-guanidine. J. Biochem. Mol. Toxicol. 18, 69–77 (2004).[CrossRef][Medline]
  45. Deneke, S.M. Thiol-based antioxidants: Curr. Top. Cell. Regul. 36, 151–180 (2006).
  46. Renschler, M.F. The emerging role of reactive oxygen species in cancer therapy. Eur. J. Cancer 40, 1934–1940 (2004).[CrossRef][Medline]
  47. Kotamraju, S., Konorev, E.A., Joseph, J., and Kalyanaraman, B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: Role of reactive oxygen and nitrogen species. J. Biol. Chem. 275, 33585–33592 (2000).[Abstract/Free Full Text]
  48. Doroshow, J.H., Locker, G.Y., and Myers, C.E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. Clin. Invest. 65, 128–135 (1980).
  49. Quint, P., Reutzel, R., Mikulski, R., McKenna, R., and Silverman, D.N. Crystal structure of nitrated human manganese superoxide dismutase: Mechanism of inactivation. Free Rad. Biol. Med. 40, 453–458 (2006).[CrossRef][Medline]
  50. Krause, M.S., Oliveira, L.P., Silveira, E.M.S. et al. Mrp1/gs-x pump ATPase expression: Is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison to skeletal muscle cells? Cell Biochem. Funct. 25, 23–32 (2007).[CrossRef][Medline]
  51. Jungsuwadee, P., Cole, M.P., Sultana, R. et al. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol. Cancer Ther. 5, 2851–2860 (2006).[Abstract/Free Full Text]
  52. Soontornmalai, A., Vlaming, M.L.H., and Fritschy, J.M. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 138, 159–169 (2006).[CrossRef][Medline]
  53. Lien, Y.C., Noel, T., Liu, H., Stromberg, A J., Chen, K.C., and St Clair, D.K. Phospholipase c-delta 1 is a critical target for tumor necrosis factor receptor-mediated protection against Adriamycin-induced cardiac injury. Cancer Res. 66, 4329–4338 (2006).[Abstract/Free Full Text]
  54. Tokarska-Schlattner, M., Wallimann, T., and Schlattner, U. Multiple interference of anthracyclines with mitochondrial creatine kinases: Preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol. 61, 516–523 (2002).[Abstract/Free Full Text]
  55. Chen, Y.M., Daosukho, C., Opii, W.O. et al. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. Free Rad. Biol. Med. 41, 1470–1477 (2006).[CrossRef][Medline]
  56. Butterfield, D.A., Perluigi, M., and Sultana, R. Oxidative stress in Alzheimer’s disease brain: New insights from redox proteomics. Eur. J. Pharmacol. 545, 39–50 (2006).[CrossRef][Medline]
  57. Anderson, S., Bankier, A.T., Barrell, B.G. et al. Sequence and organization of the human mitochondrial genome. Nature 290, 457–465 (1981).[CrossRef][Medline]
  58. Tsutsui, H., Ide, T., and Kinugawai, S. Mitochondrial oxidative stress, DNA damage, and heart failure. Antioxid. Redox Signal. 8, 1737–1744 (2006).[CrossRef][Medline]
  59. Wallace, D.C. Mitochondrial defects in cardiomyopathy and neuromuscular disease. Am. Heart J. 139, S70–S85 (2000).[CrossRef][Medline]
  60. Wallace, D.C., Ye, J.H., Neckelmann, S.N., Singh, G., Webster, K.A., and Greenberg, B.D. Sequence-analysis of cDNAs for the human and bovine ATP synthase beta-subunit: Mitochondrial DNA genes sustain seventeen times more mutations. Curr. Genet. 12, 81–90 (1987).[CrossRef][Medline]
  61. Nithipongvanitch, R., Ittarat, W., Velez, J.M., Zhao, R., St. Clair, D.K., and Oberley, T.D. Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute Adriamycin treatment. J. Histochem. Cytochem.55, 629–639 (2207).[CrossRef]
  62. Lebrecht, D., Setzer, B., Ketelsen, U.-P., Haberstroh, J., and Walker, U.A. Time-dependent and tissue-specific accumulation of mtdna and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108, 2423–2429 (2003).[Abstract/Free Full Text]
  63. Lebrecht, D., Kokkori, A., Ketelsen, U. P., Setzer, B., and Walker, U.A. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to Doxorubicin. J. Pathol. 207, 436–444 (2005).[CrossRef][Medline]
  64. Serrano, J., Palmeira, C.M., Kuehl, D.W., Wallace, K.B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic Doxorubicin administration. Biochim. Biophy. Acta 1411, 201–205 (1999). This paper, together with references 62 and 63, provided evidence on the association between mitochondrial DNA damage and DOX cardiotoxicity.[Medline]
  65. Anan, R., Nakagawa, M., Miyata, M. et al. Cardiac involvement in mitochondrial diseases - a study on 17 patients with documented mitochondrial-dna defects. Circulation 91, 955–961 (1995).[Abstract/Free Full Text]
  66. Martin, L.J. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J. Neuropathol. Exper. Neurol. 65, 1103–1110 (2006).[Medline]
  67. Giantris, A., Abdurrahman, L., Hinkle, A., Asselin, B., and Lipshultz, S.E. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. 27, 53–68 (1998).[Medline]
  68. Krischer, J.P., Epstein, S., Cuthbertson, D.D., Goorin, A.M., Epstein, M.L., and Lipshultz, S.E. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The pediatric oncology group experience. J. Clin. Oncol. 15, 1544–1552 (1997).[Abstract]
  69. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous-infusion. Ann. Intern. Med. 96, 133–139 (1982).[CrossRef][Medline]
  70. Lipshultz, S.E., Giantris, A.L., Lipsitz, S.R. et al. Doxorubicin administration by continuous infusion is not cardioprotective: The dana-farber 91-01 acute lymphoblastic leukemia protocol. J. Clin. Oncol. 20, 1677–1682 (2002).[Abstract/Free Full Text]
  71. Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B.V., and Dombernowsky, P. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 16, 3502–3508 (1998).[Abstract]
  72. Perez, D.J., Harvey, V.J., Robinson, B.A. et al. A randomized comparison of single-agent doxorubicin and epirubicin as 1st-line cytotoxic therapy in advanced breast-cancer. J. Clin. Oncol. 9, 2148–2152 (1991).[Abstract]
  73. Anderlini, P., Benjamin, R.S., Wong, F.C. et al. Idarubicin cardiotoxicity - a retrospective study in acute myeloid-leukemia and myelodysplasia. J. Clin. Oncol. 13:2827–2834 (1995).[Abstract]
  74. Creutzig, U., Ritter, J., Zimmermann, M., et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study of AML-BFM 93. Leukemia 15, 348–354 (2001).[CrossRef][Medline]
  75. Abali, H. and Celik, I. High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetax-el. Am. J. Clin. Oncol. 25, 632–633 (2002).[Medline]
  76. Marty, M., Espie, M., Llombart, A., Monnier, A., Rapoport, B.L., and Stahalova, V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann. Oncol. 17, 614–622 (2006).[Abstract/Free Full Text]
  77. Minotti, G., Cairo, G., and Monti, E. Role of iron in anthracycline cardiotoxicity: New tunes for an old song? FASEB J. 13, 199–212 (1999).[Abstract/Free Full Text]
  78. Tebbi, C.K., London, W.B., Friedman, D. et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J. Clin. Oncol. 25, 493–500 (2007).[Abstract/Free Full Text]
  79. Sanganahalli, B.G., Joshi, P.G., and Joshi, N.B. Xanthine oxidase, nitric oxide synthase and phospholipase a2 produce reactive oxygen species via mitochondria. Brain Res. 1037, 200–203 (2005).[CrossRef][Medline]
  80. Prabhakaran, K., Li, L., Borowitz, J.L., and Isom, G.E. Inducible nitric oxide synthase up-regulation and mitochondrial glutathione depletion mediate cyanide-induced necrosis in mesencephalic cells. J. Neurosci. Res. 84, 1003–1011 (2006).[CrossRef][Medline]
  81. Yen, H.C., Oberley, T.D., Vichitbandha, S., Ho, Y.S., and St Clair, D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98, 1253–1260 (1996). This was the study that showed modulation of MnSOD, a mitochondrial antioxidant enzyme, could protect against DOX cardiotoxicity, suggesting that a SOD mimetic could be used as an intervention strategy.[Medline]
  82. Kang, Y.J., Sun, X., Chen, Y., Zhou, Z. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. Chem. Res. Toxicol. 15, 1–6 (2002).[CrossRef][Medline]
  83. Sun, X., Zhou, Z., and Kang, Y.J. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res. 61, 3382–3387 (2001).[Abstract/Free Full Text]
  84. Shioji, K., Kishimoto, C., Nakamura, H. et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106, 1403–1409 (2002).[Abstract/Free Full Text]
  85. Konorev, E. A., Kennedy, M.C., and Kalyanaraman, B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: The role of reactive oxygen and nitrogen intermediates. Arch. Biochem. Biophys. 368, 421–428 (1999).[CrossRef][Medline]
  86. Zhang, X.Y., Li, W.G., Wu, Y.J., and Gao, M.T. Amelioration of doxorubicin-induced myocardial oxidative stress and immunosuppression by grape seed proanthocyaniclins in tumour-bearing mice. J. Pharm. Pharmacol. 57, 1043–1051 (2005).[CrossRef][Medline]




This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.
Right arrow Articles by St. Clair, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.
Right arrow Articles by St. Clair, D. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews